Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials
Year: 2020
Type: article
Abstract: INTRODUCTION: The phase 2 POPLAR and phase 3 OAK studies of the anti-programmed death-ligand 1 (PD-L1) immunotherapy atezolizumab in patients with previously treated advanced NSCLC revealed significant improvements in survival versus docetaxel (p = 0.04 and 0.0003, respectively). Longer follow-up permits evaluation of continued benefit of atezolizumab. This study reports the final overall survival (OS) and safety findings from both trials. METHODS: ) every 3 weeks. Efficacy and safety outcomes were evaluated. RESULTS: A longer OS was observed in patients receiving atezolizumab versus docetaxel in POPLAR (median OS = 12.6 mo versus 9.7 mo; hazard ratio = 0.76, 95% confidence interval [CI]: 0.58-1.00) and OAK (median OS = 13.3 versus 9.8 mo; hazard ratio = 0.78, 95% CI: 0.68-0.89). The 4-year OS rates in POPLAR were 14.8% (8.7-20.8) and 8.1% (3.2-13.0) and those in OAK were 15.5% (12.4-18.7) and 8.7% (6.2-11.3) for atezolizumab and docetaxel, respectively. Atezolizumab had improved OS benefit compared with docetaxel across all PD-L1 expression and histology groups. Most 4-year survivors in the docetaxel arms received subsequent immunotherapy (POPLAR, 50%; OAK, 65%). Of the 4-year survivors, most had Eastern Cooperative Oncology Group performance status of 0 and nonsquamous histological classification and approximately half were responders (POPLAR: atezolizumab, seven of 15; docetaxel, three of four; OAK: atezolizumab, 24 of 43; docetaxel, 11 of 26). Treatment-related grade 3/4 adverse events occurred in 27% and 16% of atezolizumab 4-year survivors in POPLAR and OAK, respectively. CONCLUSIONS: Long-term follow-up suggests a consistent survival benefit with atezolizumab versus docetaxel in patients with previously treated NSCLC regardless of PD-L1 expression, histology, or subsequent immunotherapy. Atezolizumab had no new safety signals, and the safety profile was similar to that in previous studies.
Source: Journal of Thoracic Oncology
Institutions: Université Toulouse III - Paul Sabatier, Centre Hospitalier Universitaire de Toulouse, Henry Ford Hospital, Aichi Cancer Center, Aichi Cancer Center Hospital, UC Davis Comprehensive Cancer Center, Azienda Ospedaliera San Gerardo, Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Genentech, Samsung Medical Center, Sungkyunkwan University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: docetaxel, non-small cell lung cancer, PD-L1 inhibitors, immune checkpoint inhibitors, overall survival, POPLAR trial, OAK trial, long-term survival, treatment-related adverse events, PD-L1 expression, previously treated patients, immunotherapy response, performance status, long-term follow-up, anti-PD-1 therapy
Open Access status: hybrid
Estimated APC paid: $2,800
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Astellas Pharma US, AstraZeneca, Merck, Novartis, Roche, AbbVie, Boehringer Ingelheim, Takeda Pharmaceutical Company, Taiho Pharmaceutical, Novocure, Les Laboratories Pierre Fabre, Kissei, Boehringer Ingelheim Japan, Daiichi-Sankyo, Astellas Pharma, Ono Pharmaceutical, Genentech, Merck Sharp and Dohme, Chugai Pharmaceutical, Daiichi Sankyo Europe, Janssen Japan
OpenAlex ID: W3095297211
